Denali Therapeutics (NASDAQ:DNLI) Earns “Buy” Rating from BTIG Research

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research note issued on Monday,Benzinga reports. They currently have a $39.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 98.78% from the stock’s current price.

DNLI has been the topic of several other research reports. The Goldman Sachs Group raised their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Leerink Partners lowered their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Robert W. Baird raised their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Stifel Nicolaus raised their price objective on shares of Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $19.62 on Monday. The business’s 50 day moving average is $20.19 and its two-hundred day moving average is $18.86. The company has a market cap of $3.11 billion, a PE ratio of -6.81 and a beta of 0.99. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter last year, the company posted ($0.78) earnings per share. Equities analysts predict that Denali Therapeutics will post -2.86 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in Denali Therapeutics during the second quarter worth $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics during the third quarter worth $29,000. State of Wyoming acquired a new stake in Denali Therapeutics during the second quarter worth $29,000. Fifth Third Bancorp acquired a new stake in Denali Therapeutics during the first quarter worth $55,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Denali Therapeutics during the fourth quarter worth $57,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.